Physician profile
Brett Waldman
NPI 1407192289
$7,035.54
in general payments reported to CMS, 2019-2025
30 companies · $1,353 in 2025
The $1,353 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,260 · 2020: $476 · 2021: $209 · 2022: $711 · 2023: $1,324 · 2024: $1,703 · 2025: $1,353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,380.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,207.85 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $846.86 | 2019-2024 | Xarelto |
| Atricure, INC. | $846.80 | 2022-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Amgen INC. | $676.09 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $617.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $397.17 | 2021-2025 | Verquvo, Steglatro, Steglujan |
| E.R. Squibb & Sons, L.L.C. | $367.39 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $350.00 | 2019-2025 | Farxiga |
| Philips North America LLC | $278.91 | 2022-2025 | Mcot, Extended Holter, (5050) Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.02 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $187.50 | 2019-2025 | Lifevest |
| Novo Nordisk INC | $133.97 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Scpharmaceuticals INC. | $125.45 | 2024-2025 | |
| Boston Scientific Corporation | $120.53 | 2019-2024 | Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $90.69 | 2021-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $66.79 | 2023 | Definity |
| W. L. Gore & Associates, INC. | $54.97 | 2019-2021 | |
| Impulse Dynamics (USA) INC. | $51.50 | 2025 | Optimizer |
| Esperion Therapeutics, INC. | $49.44 | 2025 | Nexletol |
| Cvrx, INC. | $49.36 | 2024-2025 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $46.12 | 2019-2024 | Evkeeza |
| Corcept Therapeutics | $44.73 | 2023-2025 | Korlym |
| Alnylam Pharmaceuticals INC. | $30.65 | 2025 | Amvuttra, Onpattro |
| Sanofi-Aventis U.S. LLC | $26.62 | 2020-2021 | |
| Ge Healthcare | $21.83 | 2024 | |
| Valeritas, INC. | $18.93 | 2019 | |
| Ardelyx, INC. | $17.60 | 2024 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.46 | 2020 | |
| Ironwood Pharmaceuticals, INC | $13.72 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.